These findings highlight the potential of the EGR1/miR-139/NRF2 axis as a diagnostic therapeutic target and biomarker for improving radiosensitivity in NSCLC (Zhang et al., 2024b). The gene discussed is EGR1; the disease is non-small cell lung carcinoma.